454 related articles for article (PubMed ID: 26677336)
21. Focus on Nintedanib in NSCLC and Other Tumors.
Manzo A; Carillio G; Montanino A; Costanzo R; Sandomenico C; Rocco G; Morabito A
Front Med (Lausanne); 2016; 3():68. PubMed ID: 28066768
[TBL] [Abstract][Full Text] [Related]
22. Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory to Standard Treatment.
Van Cutsem E; Yoshino T; Hocke J; Oum'Hamed Z; Studeny M; Tabernero J
Clin Colorectal Cancer; 2016 Mar; 15(1):91-94.e1. PubMed ID: 26603056
[TBL] [Abstract][Full Text] [Related]
23. Strategies targeting angiogenesis in advanced non-small cell lung cancer.
Wang J; Chen J; Guo Y; Wang B; Chu H
Oncotarget; 2017 Aug; 8(32):53854-53872. PubMed ID: 28881856
[TBL] [Abstract][Full Text] [Related]
24. Nintedanib in ovarian cancer.
Khalique S; Banerjee S
Expert Opin Investig Drugs; 2017 Sep; 26(9):1073-1081. PubMed ID: 28721753
[TBL] [Abstract][Full Text] [Related]
25. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
26. Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer.
Socinski MA
Cancer Treat Rev; 2011 Dec; 37(8):611-7. PubMed ID: 21641723
[TBL] [Abstract][Full Text] [Related]
27. The role of antiangiogenetic agents in the treatment of breast cancer.
Bareschino MA; Schettino C; Colantuoni G; Rossi E; Rossi A; Maione P; Ciardiello F; Gridelli C
Curr Med Chem; 2011; 18(33):5022-32. PubMed ID: 22050750
[TBL] [Abstract][Full Text] [Related]
28. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications.
Eskander RN; Tewari KS
Gynecol Oncol; 2014 Feb; 132(2):496-505. PubMed ID: 24316305
[TBL] [Abstract][Full Text] [Related]
29. Nintedanib for Advanced Epithelial Ovarian Cancer: A Change of Perspective? Summary of Evidence from a Systematic Review.
Barra F; Laganà AS; Ghezzi F; Casarin J; Ferrero S
Gynecol Obstet Invest; 2019; 84(2):107-117. PubMed ID: 30304728
[TBL] [Abstract][Full Text] [Related]
30. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
[TBL] [Abstract][Full Text] [Related]
31. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
Teoh D; Secord AA
Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
[TBL] [Abstract][Full Text] [Related]
32. Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC.
Ballas MS; Chachoua A
Onco Targets Ther; 2011; 4():43-58. PubMed ID: 21691577
[TBL] [Abstract][Full Text] [Related]
33. Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity.
Tai WT; Shiau CW; Li YS; Chang CW; Huang JW; Hsueh TT; Yu HC; Chen KF
J Hepatol; 2014 Jul; 61(1):89-97. PubMed ID: 24657398
[TBL] [Abstract][Full Text] [Related]
34. Angiogenesis Inhibitors in Small Cell Lung Cancer.
Montanino A; Manzo A; Carillio G; Palumbo G; Esposito G; Sforza V; Costanzo R; Sandomenico C; Botti G; Piccirillo MC; Cascetta P; Pascarella G; La Manna C; Normanno N; Morabito A
Front Oncol; 2021; 11():655316. PubMed ID: 34123809
[TBL] [Abstract][Full Text] [Related]
35. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
36. Angiogenesis inhibitors and vascular disrupting agents in non-small cell lung cancer.
Rossi A; Maione P; Ferrara ML; Sacco PC; Schettino C; Bareschino MA; Gridelli C
Curr Med Chem; 2009; 16(30):3919-30. PubMed ID: 19747132
[TBL] [Abstract][Full Text] [Related]
37. Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer.
Syrios J; Nintos G; Georgoulias V
Expert Rev Anticancer Ther; 2015; 15(8):875-84. PubMed ID: 26204906
[TBL] [Abstract][Full Text] [Related]
38. Nintedanib in NSCLC: evidence to date and place in therapy.
Bronte G; Passiglia F; Galvano A; Barraco N; Listì A; Castiglia M; Rizzo S; Fiorentino E; Bazan V; Russo A
Ther Adv Med Oncol; 2016 May; 8(3):188-97. PubMed ID: 27239237
[TBL] [Abstract][Full Text] [Related]
39. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
Leite de Oliveira R; Hamm A; Mazzone M
Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
[TBL] [Abstract][Full Text] [Related]
40. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
